ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
Inclusion Criteria:
Exclusion Criteria:
Chapel Hill, North Carolina 27599, United States
Madison, Wisconsin 53792, United States
Kurralta Park, New South Wales 5037, Australia
East Bentleigh, Victoria 3165, Australia
Meldola (FC), 47014, Italy
Surrey, England GU2 7WG, United Kingdom
Surrey, England SM2 5PT, United Kingdom